Memory Clinic

Memory Clinic

Memory Clinic & Cognitive Neurology Program.

Comprehensive cognitive assessment, precision diagnosis, advanced biomarker testing, and personalized treatment for memory disorders and dementia

Memory problems do not always mean dementia, and dementia is not a single disease. Cognitive symptoms may result from Alzheimer's disease, cerebrovascular disease, other neurodegenerative conditions, medical disorders, medications, sleep or mood disorders, or a combination of factors. Our Memory Clinic follows a structured diagnostic pathway designed to determine three fundamental questions: What is the patient's cognitive profile? What is causing the cognitive impairment? What stage of disease is present? Assessment is individualized according to age, education, language, cultural background, medical history, functional status, and clinical presentation. Patients may undergo cognitive screening, comprehensive neuropsychological assessment, neurological examination, advanced brain imaging, laboratory investigations, and Alzheimer's disease biomarker testing. Where appropriate, blood-based biomarkers can form part of the initial Alzheimer's disease diagnostic pathway, with cerebrospinal fluid biomarkers or amyloid PET imaging used when additional or confirmatory assessment is clinically indicated. Following diagnosis, an individualized care plan is developed. This may include treatment of reversible contributors, optimization of vascular risk factors, cognitive and functional interventions, symptomatic treatment, patient and caregiver education, and disease-modifying Alzheimer's therapy for eligible patients.

Comprehensive cognitive & neuropsychological assessment
Advanced Alzheimer's diagnostics: blood biomarkers, CSF biomarkers & amyloid PET
Multidisciplinary Memory Clinic Board
Disease-modifying Alzheimer's therapies with structured MRI & cognitive monitoring

Common Conditions & Subspecialty Clinics.

Procedures & Treatments.

  • Advanced Alzheimer’s & Dementia Diagnostics

Care Pathway & Coordination.

1
Comprehensive Memory Clinic Pathway (H3)

Comprehensive Memory Clinic Pathway (H3)

Memory or cognitive concern -> Cognitive screening -> Neurologist assessment -> Neuropsychological evaluation -> Brain MRI & laboratory investigations -> Alzheimer's biomarker testing when indicated -> Multidisciplinary Memory Clinic Board -> Personalized diagnosis & treatment plan -> Long-term clinical and cognitive monitoring Our coordinated approach integrates clinical history, neurological examination, neuropsychological findings, imaging, laboratory results, functional assessment, and biomarkers. Complex or diagnostically uncertain cases can be discussed within the multidisciplinary Memory Clinic Board, allowing the different components of the assessment to be interpreted together and a unified management plan to be developed.

2
Early Alzheimer's Disease & Disease-Modifying Therapy Pathway (H3)

Early Alzheimer's Disease & Disease-Modifying Therapy Pathway (H3)

Patients with mild cognitive impairment or mild dementia suspected to be caused by Alzheimer's disease may undergo a dedicated treatment-evaluation pathway: Clinical & neuropsychological assessment -> Confirmation of appropriate disease stage -> Alzheimer's disease biomarker confirmation -> APOE assessment and counseling when appropriate -> Baseline MRI & treatment-safety evaluation -> Multidisciplinary eligibility review -> Shared treatment decision -> Treatment initiation -> Scheduled MRI and clinical safety monitoring -> Longitudinal cognitive follow-up This pathway provides structured patient selection and monitoring throughout disease-modifying therapy.

Technology &Facilities

  • The Memory Clinic provides access to advanced diagnostic, biomarker, imaging, and treatment capabilities within an integrated cognitive-care pathway.

  • Advanced brain MRI with dedicated cognitive and dementia imaging protocols

  • Blood-based Alzheimer's disease biomarkers

  • Cerebrospinal fluid Alzheimer's disease biomarkers, including amyloid and tau

  • Amyloid PET imaging for assessment of cerebral amyloid pathology

  • APOE genotyping for selected patients, including assessment before anti-amyloid therapy when appropriate

  • Comprehensive neuropsychological assessment

  • Dedicated infusion facilities for disease-modifying Alzheimer's therapies

  • Structured MRI surveillance for amyloid-related imaging abnormalities (ARIA)

  • Longitudinal cognitive and neuropsychological monitoring

  • Multidisciplinary Memory Clinic Board

  • Together, these capabilities allow patients to move through assessment, biomarker confirmation, diagnosis, treatment selection, therapy, and follow-up within one coordinated program.

Our Experts.

Dr. Farah Azri Negadi

Dr. Farah Azri Negadi

Consultant Neurologist
Dr. Nazir Sharaf

Dr. Nazir Sharaf

Consultant Neurologist
Dr. Ashraf Ali Soliman

Dr. Ashraf Ali Soliman

Neurology Specialist

Frequently Asked Questions.

Is memory loss a normal part of aging?

Some slowing of information processing and occasional difficulty retrieving information can occur with normal aging. Progressive memory loss, repeated questions, difficulty managing medications or finances, getting lost, changes in language or judgment, or declining ability to perform usual activities should be evaluated.

Does having memory problems mean I have Alzheimer's disease?

No. Memory and cognitive problems have many possible causes, including other neurological disorders, cerebrovascular disease, sleep disorders, mood disorders, medications, and potentially reversible medical conditions. A comprehensive assessment helps determine the underlying cause.

What is mild cognitive impairment?

Mild cognitive impairment, or MCI, describes measurable cognitive decline greater than expected for normal aging while everyday independence remains relatively preserved. MCI can have several causes and does not automatically mean that a person will develop dementia.

How is Alzheimer's disease diagnosed?

Diagnosis begins with clinical and cognitive assessment and usually includes brain imaging and laboratory investigations. Alzheimer's disease biomarkers can provide evidence of the underlying disease process and may be particularly important when disease-modifying treatment is being considered.

Are there blood tests for Alzheimer's disease?

Yes. Blood-based biomarkers can provide information about biological changes associated with Alzheimer's disease and can be incorporated into the diagnostic pathway. Their interpretation depends on the clinical situation, and additional testing such as cerebrospinal fluid biomarkers or amyloid PET may sometimes be appropriate.

What are CSF biomarkers and amyloid PET?

Cerebrospinal fluid testing measures biomarkers associated with amyloid and tau pathology. Amyloid PET is a specialized imaging technique that can demonstrate amyloid deposition in the brain. Both can help establish whether Alzheimer's disease pathology is present.

What happens during a neuropsychological assessment?

Neuropsychological assessment evaluates different areas of cognition, including memory, attention, language, executive function, processing speed, and visuospatial abilities. The pattern of strengths and weaknesses can help differentiate between causes of cognitive impairment and provides a baseline for future monitoring.

Can a cognitive screening test alone diagnose dementia?

No. Screening tests can identify possible cognitive impairment but should not be interpreted in isolation. Education, language, cultural background, medical history, daily functioning, neurological assessment, imaging, and other investigations may all influence the diagnosis.

Can Alzheimer's disease be treated?

Yes. Treatment depends on disease stage and the individual patient. Management may include symptomatic medications, treatment of contributing medical conditions, management of vascular risk factors, cognitive and lifestyle interventions, and patient and caregiver support. For appropriately selected patients with early Alzheimer's disease, disease-modifying therapies targeting the underlying disease process may also be considered.

What are anti-amyloid therapies?

Anti-amyloid therapies are disease-modifying treatments designed to reduce amyloid pathology associated with Alzheimer's disease. They are intended for carefully selected patients in the early symptomatic stages of Alzheimer's disease. Treatment requires confirmation of underlying Alzheimer pathology, assessment of treatment suitability, shared decision-making, and structured safety monitoring.

Why is APOE testing performed before anti-amyloid therapy?

APOE genotype can provide clinically relevant information when assessing treatment-related risk, particularly the risk of amyloid-related imaging abnormalities (ARIA). Testing should therefore be accompanied by appropriate counseling and discussion of what the result may mean for treatment decisions.

Why are MRI scans required during anti-amyloid treatment?

Anti-amyloid therapies can be associated with amyloid-related imaging abnormalities, or ARIA. MRI is used before treatment and at defined intervals during therapy to identify these changes and help guide safe treatment. Can vascular risk factors affect memory?

How often should cognitive testing be repeated?

The timing depends on the diagnosis, clinical course, and treatment. Repeat cognitive or neuropsychological assessment may be used to monitor progression, clarify an uncertain diagnosis, assess meaningful clinical change, and follow patients receiving specific therapies.

Ready to Start Your Health Journey?

Take the first step towards better health with our expert team.

Book Appointment Contact Us

Call Now Appointment